Using targeted radiotherapy to improve outcomes in men with metastatic prostate cancer
Ablative Radiotherapy to Consolidate Maximal Systemic Response in Metastatic Prostate Cancer (ANCHOR-Prostate)
This study is testing if a special type of targeted radiotherapy can help men with advanced prostate cancer who have responded well to standard treatments stay healthy longer.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Sex | Male |
| Sponsor | Centre hospitalier de l'Université de Montréal (CHUM) Academic / other |
| Locations | 1 site (Montreal, Quebec) |
| Trial ID | NCT05457699 on ClinicalTrials.gov |
What this trial studies
This phase II clinical trial investigates the effectiveness of Stereotactic Ablative Body Radiotherapy (SABR) in men with metastatic prostate cancer who have achieved a maximal systemic response to standard therapy. Eighty participants will be randomly selected to receive SABR based on disease detected by PSMA-PET imaging. The primary goal is to evaluate the rate of freedom from progression (FFP) at one year, with patients categorized by hormone sensitivity prior to randomization. The study aims to provide insights into the potential benefits of consolidative radiotherapy in this patient population.
Who should consider this trial
Good fit: Ideal candidates are men diagnosed with metastatic prostate cancer who have achieved a stable PSA response to systemic therapy and have PSMA-PET detected disease suitable for SABR.
Not a fit: Patients with hormone-resistant metastatic prostate cancer who do not meet the eligibility criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve progression-free survival in men with metastatic prostate cancer.
How similar studies have performed: Similar studies using SABR for metastatic prostate cancer have shown promising results, indicating potential for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Enrolled in PERa (CHUM CER 17.032) and randomly selected for ANCHOR-Prostate. * Diagnosis of hormone-sensitive metastatic prostate cancer having responded to systemic therapy. * PSA non-progressing * ECOG 0-2 * Metastatic disease suitable for MDRT. * Primary tumor must have received definitive local treatment (surgery or radiotherapy) with no evidence of local recurrence, or be planned for treatment at the time of MDRT. Exclusion Criteria: * Planned intermittent systemic therapy. * Planned radio-ligand therapy.
Where this trial is running
Montreal, Quebec
- Crchum — Montreal, Quebec, Canada (Recruiting)
Study contacts
- Study coordinator: Mom Phat
- Email: mom.phat.chum@ssss.gouv.qc.ca
- Phone: 514-890-8254
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.